Hemoglobin A1c Testing Market to Spike to $1.6 Billion by 2017

Hemoglobin A1c Testing Market to Spike to $1.6 Billion by 2017 
NEW YORK, NY -- (Marketwire) -- 03/11/13 --  TriMarkPublications.com
cites in its newly published "Hemoglobin A1c Testing Markets" report
that the hemoglobin A1c testing market will spike to $1.6 billion by
2017. For more information, visit:
Hemoglobin A1c testing can be categorized into three main modalities:
clinical laboratory HbA1c testing, point of care HbA1c testing and
physician office laboratories (POL) HbA1c testing. The POC segment
occupies nearly one third of the total hemoglobin A1c testing market
and is one of the fastest growing areas, with a CAGR of 12.7% between
2012 and 2017. The U.S. hemoglobin A1c testing market is projected to
grow to $518 million in 2017. Combined, the developed regions
comprise greater than 75% of the total hemoglobin A1c testing market. 
The "Hemoglobin A1c Testing Markets" report covers: 

--  Diabetes
--  Pre-Diabetes Syndrome
--  Metabolic Syndrome
--  High-Performance Liquid Chromatography (HPLC)
--  Immunoassays
--  Boronate Affinity Chromatography
--  Enzymatic Assay
--  Micro-Optical Detection Methods
--  Diabetes Control and Complications Trial (DCCT)
--  National Glycohemoglobin Standardization Program (NGSP)
--  International Federation of Clinical Chemistry (IFCC)
--  A1c Derived Average Glucose (ADAG)

The "Hemoglobin A1c Testing Markets" report examines companies
manufacturing hemoglobin A1c testing equipment and supplies in the
world. Companies covered include: A. Menarini, Abbott, Alere, Arkray,
Axis-Shield, Bayer Healthcare, Beckman Coulter, Bio-Rad, EKF,
Infopia, Ortho Clinical, Quotient, Randox, Roche, Siemens, Tosoh and
Detailed charts with sales forecasts and marketshare data are
included. For more information, visit:
About TriMarkPublications.com 
TriMarkPublications.com is a global leader in the biotechnology,
healthcare and life sciences market research publishing. For more
information, please visit http://www.trimarkpublications.com.  
Important Notice 
The statements contained in this news release that are
forward-looking are based on current expectations that are subject to
a number of uncertainties and risks, and actual results may differ
Media Relations
Press spacebar to pause and continue. Press esc to stop.